全文获取类型
收费全文 | 10183篇 |
免费 | 872篇 |
国内免费 | 244篇 |
专业分类
耳鼻咽喉 | 116篇 |
儿科学 | 219篇 |
妇产科学 | 289篇 |
基础医学 | 1657篇 |
口腔科学 | 148篇 |
临床医学 | 811篇 |
内科学 | 2178篇 |
皮肤病学 | 255篇 |
神经病学 | 831篇 |
特种医学 | 212篇 |
外科学 | 1033篇 |
综合类 | 669篇 |
现状与发展 | 1篇 |
一般理论 | 4篇 |
预防医学 | 795篇 |
眼科学 | 171篇 |
药学 | 924篇 |
3篇 | |
中国医学 | 227篇 |
肿瘤学 | 756篇 |
出版年
2024年 | 19篇 |
2023年 | 147篇 |
2022年 | 250篇 |
2021年 | 549篇 |
2020年 | 340篇 |
2019年 | 418篇 |
2018年 | 539篇 |
2017年 | 377篇 |
2016年 | 384篇 |
2015年 | 394篇 |
2014年 | 559篇 |
2013年 | 652篇 |
2012年 | 846篇 |
2011年 | 894篇 |
2010年 | 481篇 |
2009年 | 383篇 |
2008年 | 520篇 |
2007年 | 534篇 |
2006年 | 519篇 |
2005年 | 420篇 |
2004年 | 422篇 |
2003年 | 462篇 |
2002年 | 441篇 |
2001年 | 207篇 |
2000年 | 105篇 |
1999年 | 83篇 |
1998年 | 55篇 |
1997年 | 57篇 |
1996年 | 32篇 |
1995年 | 21篇 |
1994年 | 26篇 |
1993年 | 11篇 |
1992年 | 14篇 |
1991年 | 10篇 |
1990年 | 11篇 |
1989年 | 9篇 |
1988年 | 9篇 |
1987年 | 8篇 |
1983年 | 6篇 |
1982年 | 5篇 |
1981年 | 6篇 |
1979年 | 8篇 |
1978年 | 5篇 |
1977年 | 3篇 |
1975年 | 5篇 |
1974年 | 3篇 |
1973年 | 8篇 |
1972年 | 4篇 |
1968年 | 5篇 |
1965年 | 3篇 |
排序方式: 共有10000条查询结果,搜索用时 46 毫秒
1.
Qiangsheng He Chongfei Huang Xiwen Qin Yuanyuan Yu Di Tang Junjie Huang Zi Chong Kuo Yuyao Ling Deli Mao Bin Xia Wenjing Li Kuiqing Lu Man Yang Yulong He Wenbo Meng Jinqiu Yuan Yihang Pan 《International journal of cancer. Journal international du cancer》2023,153(5):942-949
Recent epidemiological studies suggested that proton pump inhibitor (PPI) use was associated with an increased risk of biliary tract cancer (BTC), however, confounders were not adequately controlled. Our study aimed to evaluate PPI use and subsequent risk of BTC and its subtypes in three well-established cohorts. We conducted a pooled analysis of the subjects free of cancers in UK Biobank (n = 463 643), Nurses' Health Study (NHS, n = 80 235) and NHS II (n = 95 869). Propensity score weighted Cox models were used to estimate marginal HRs of PPIs use on BTC risk, accounting for potential confounders. We documented 284 BTC cases in UK Biobank (median follow-up: 7.6 years), and 91 cases in NHS and NHS II cohorts (median follow-up: 15.8 years). In UK biobank, PPI users had a 96% higher risk of BTC compared to nonusers in crude model (HR 1.96, 95% CI 1.44-2.66), but the effect was attenuated to null after adjusting for potential confounders (HR 0.95, 95% CI 0.60-1.49). PPI use was not associated with risk of BTC in the pooled analysis of three cohorts (HR 0.93, 95% CI 0.60-1.43). We also observed no associations between PPI use with risk of intrahepatic (HR 1.00, 95% CI 0.49-2.04), extrahepatic bile duct (HR 1.09, 95% CI 0.52-2.27) and gallbladder cancers (HR 0.66, 95% CI 0.26-1.66) in UK Biobank. In summary, regular use of PPIs was not associated with the risk of BTC and its subtypes. 相似文献
2.
3.
4.
Luis Veloza Cristina Teixido Natalia Castrejon Fina Climent Ana Carri Marta Marginet Davide Soldini Blanca Gonzlez‐Farr Inmaculada Ribera‐Cortada Armando Lopez‐Guillermo Eva Gonzlez‐Barca Adriana Sierra Mileyka Herrera Cndida Gmez Adriana Garcia Olga Balagu Elias Campo Antonio Martinez 《Histopathology》2019,75(6):799-812
5.
Inflammation but not obesity or insulin resistance is associated with increased plasma fibroblast growth factor 23 concentration in the elderly 下载免费PDF全文
6.
Susan C. Fox Jane A. May Natalia Dovlatova Jackie R. Glenn Andrew Johnson Ann E. White 《Platelets》2019,30(3):290-295
Measurement of P-selectin on activated platelets as a means of measuring platelet function utilizing the technology described here has the advantage of not requiring immediate access to specialist equipment and expertise. Blood samples are activated, fixed, stored, and transported to a central laboratory for flow cytometric analysis. Here we have compared P-selectin with other more traditional approaches to measuring platelet function in blood and/or platelet-rich plasma (PRP) from patients with acute coronary syndromes on treatment for at least 1 month with either aspirin and clopidogrel or aspirin with prasugrel. The comparators were light transmission aggregometry (LTA), VerifyNow and Multiplate aggregometry (for determining the effects of aspirin) and LTA, VerifyNow and Multiplate together with the BioCytex VASP phosphorylation assay (for the P2Y12 antagonists). The P-selectin Aspirin Test revealed substantial inhibition of platelet function in all but three of 96 patients receiving aspirin with clopidogrel and in none of 51 patients receiving aspirin and prasugrel. The results were very similar to those obtained using LTA. There was only one patient with high residual platelet aggregation and low P-selectin expression. The same patients identified as “non-responders” to aspirin also presented with the highest residual platelet activity as measured using the VerifyNow system, although not quite as well separated from the other values. With the Multiplate test only one of these patients clearly stood out from the others. The results obtained using the P-selectin P2Y12 Test in 102 patients taking aspirin and clopidogrel were similar to the more traditional approaches in that a wide scatter of results was obtained. Generally, high values seen with the P-selectin P2Y12 Test were also high with the LTA, VerifyNow, Multiplate, and BioCytex VASP P2Y12 Tests. Similarly, low residual platelet function using the P2Y12 test was seen irrespective of the testing procedure used. However, there were differences in some patients. Prasugrel was always more effective than clopidogrel in inhibiting platelet function with none of 56 patients (P-selectin and VerifyNow), only 2 of 56 patients (Multiplate) and only 3 of 56 patients (Biocytex VASP) demonstrating high on-treatment residual platelet reactivity (HRPR) defined using previously published cut-off values. The exception was LTA where there were 11 of 56 patients with HRPR. It remains to be seen which experimental approach provides the most useful information regarding outcomes after adjusting therapies in treated patients. 相似文献
7.
8.
9.
10.